A tissue adhesion prevention hydrogel is provided and engineered with essential features for maintaining separation between tissues and organs in any part of the body, thus preventing adhesion formation, are their shear-thinning, viscoelasticity, and rapid self-healing. A method of using the tissue adhesion prevention hydrogel for tissue adhesion prevention is also provided. A method of interposing the tissue adhesion prevention in between tissue layers for tissue adhesion prevention is further provided.

A method of preventing tissue adhesion includes forming an incision in tissue, applying a hydrogel to tissue through the incision, and closing the incision with the hydrogel therein. The hydrogel includes a polymer non-covalently cross-linked with a plurality of nanoparticles and prevents a formation of adhesions between tissues and/or organs.

Provided herein are compositions including polymeric binder, for example polydopamine (PDA); a poly(N,N-dimethylacrylamide) (PDMA) polymer or a PDMA co-N-(3-Aminopropyl) Methacrylamide (APMA) polymer, and an antimicrobial peptide (AMP), methods for using the compositions to coat a substrate, and methods for making the compositions. Alternatively, the composition may include a polymeric binder or a salt thereof, high molecular weight polymer and a pharmaceutically active agent. In particular, the substrate may form part of an apparatus on which it would be beneficial to limit biofouling and/or protein binding.

The present invention includes a synthetic collagen that facilitates adhesion prevention and methods of use thereof. The present invention includes a prokaryotic collagen that facilitates adhesion prevention and treatment and methods of use thereof. The prokaryotic collagen includes an isolated and purified triple helical backbone protein that facilitates adhesion prevention: one or more alteration in a triple helical backbone protein sequence, and one or more binding motifs, wherein the isolated and purified triple helical backbone protein facilitates adhesion prevention.

The present invention provides a two-component bioink including a first solution and a second solution separately, wherein (i) the first solution includes a first biopolymer to which a first chemical functional group is introduced, and the second solution includes a second biopolymer to which a second chemical functional group able to chemically bond with the first chemical functional group is introduced; or (ii) the first solution includes a third biopolymer having a first electrostatic functional group, and the second solution includes a fourth biopolymer having a second electrostatic functional group able to physically bond with the first electrostatic functional group, a 3D biomaterial including the same, and a method for preparing the same.

Compositions and methods are provided for preparing an adhesion barrier in the form of a foldable or flexible biodegradable polymer matrix that effectively reduces, prevents or treats adhesions in a patient in need thereof. In one embodiment, the matrix comprises a first porous layer comprising collagen and a second porous layer comprising collagen and dextran, wherein the dextran is loaded in the second layer in an amount of from about 5% to about 90% by weight based on a total weight of the matrix. In some embodiments, the matrix prevents or reduces cell growth into the matrix so as to reduce or prevent adhesions. In some embodiments, the matrix is in a sheet or strip form that can be folded into a tube form.

An anti-adhesion material comprising decellularized tissues and a biocompatible polymer or fibrin glue; a method for preparing an anti-adhesion material comprising complexing a biocompatible polymer or fibrin glue to decellularized tissues; an anti-adhesion material kit comprising decellularized tissues and a biocompatible polymer or fibrin glue; a substitute biomembrane comprising decellularized tissues and a biocompatible polymer or fibrin glue; a method for preparing a substitute biomembrane comprising complexing a biocompatible polymer or fibrin glue to decellularized tissues; and a substitute biomembrane kit comprising decellularized tissues and a biocompatible polymer or fibrin glue.

There is provided a medical/cosmetic material that retains the properties which are inherent in a polyanionic polysaccharide being a raw material, that has a high level of safety because there is no need to use a chemical crosslinking agent during production, and that makes it possible to place a powder of a water-insoluble polyanionic polysaccharide at an affected area uniformly. The medical/cosmetic material includes a base and a powder dispersed in the base, in which the base contains a water-soluble salt of a first polyanionic polysaccharide, and the powder is formed by water-insolubilizing a powder of a water-soluble salt of a second polyanionic polysaccharide with a treatment liquid containing an acid anhydride.

There is provided a medical material that retains the properties which are inherent in a polyanionic polysaccharide being a raw material, that has a high level of safety because there is no need to use a chemical crosslinking agent during production, and that has a moderate strength with which a suture and the like can be conducted. The medical material is provided with a reinforcement material and a film section penetrating at least a portion of the reinforcement material to be integrated with the reinforcement material. In the medical material, the film section is formed by water-insolubilizing a film precursor section made of a raw material containing a water-soluble salt of a first polyanionic polysaccharide with a treatment liquid containing a first acid anhydride, and the reinforcement material is nonwoven fabric or woven fabric containing a biodegradable/absorbent polymer material, or a sponge-like carrier or a felt-like carrier formed by water-insolubilizing a raw material-shaped body made of a raw material containing a water-soluble salt of a second polyanionic polysaccharide with a treatment liquid containing a second acid anhydride.

Provided is a method for preventing postoperative adhesion of an organ in a wound site using the application of an antiadhesive material thereto. The antiadhesive material contains a poly--glutamic acid having a weight-average molecular weight of 600,000 to 13,000,000, or a kinematic viscosity at 37 C. of 2 cSt to 15 cSt when dissolved in distilled water at a concentration of 0.05% by mass and/or a salt thereof, as an effective ingredient. The antiadhesive material may be in a form such as powder, and therefore, for example, is easy to handle even in relatively localized surgery such as endoscopic surgery and can more reliably prevent adhesion.